KATHLYN ROWEN: Open Payments
NPI 1649300179 · WILMINGTON, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$714 in 32 payments from 9 companies in 2025. Trend: 2023 $621 · 2024 $578 · 2025 $714
Food & beverage: $714
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 4 | $199 |
| Bausch Health US, LLC | 13 | $174 |
| Alkermes, Inc. | 3 | $84 |
| Otsuka America Pharmaceutical, Inc. | 3 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $56 |
| ABBVIE INC. | 2 | $51 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| Vanda Pharmaceuticals Inc. | 2 | $32 |
| Janssen Pharmaceuticals, Inc | 1 | $17 |
Products named: INGREZZA, APLENZIN, LYBALVI, REXULTI, TRINTELLIX, VRAYLAR, Auvelity, FANAPT.
Industry payments across DE — which companies pay providers there.
